Scholarlink

<p>Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, representing around 97% of cases in humans. Mitochondria play a crucial role in slowing the progression of HCC and are utilized in developing precision medicine strategies targeting various mitochondria-related pathways. Recent developments in nanomedicine exploit the unique features of nanoparticles for improving drug delivery and efficacy specifically to mitochondria, bypassing the problems related to conventional chemotherapy. Mitochondria-targeted nanomedicines are developed for damaging mitochondrial DNA in liver cancer tissues by increasing reactive oxygen species perturbing redox balance and respiratory chain. This review emphasizes the future of mitochondrial-targeted nanomedicine in transforming liver cancer management and encourages an attempt to continuously improve these strategies to provide patients with better survival chances and quality of life.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer

  • 期刊论文

  • 发表日期：

    2025年11月18日

查看全文
  • M. Kevin,
  • Srinidhi Varadharajan,
  • P. K. Praveen Kumar,
  • Shreeiya Swaminathan,
  • R. Dharshini

摘要

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, representing around 97% of cases in humans. Mitochondria play a crucial role in slowing the progression of HCC and are utilized in developing precision medicine strategies targeting various mitochondria-related pathways. Recent developments in nanomedicine exploit the unique features of nanoparticles for improving drug delivery and efficacy specifically to mitochondria, bypassing the problems related to conventional chemotherapy. Mitochondria-targeted nanomedicines are developed for damaging mitochondrial DNA in liver cancer tissues by increasing reactive oxygen species perturbing redox balance and respiratory chain. This review emphasizes the future of mitochondrial-targeted nanomedicine in transforming liver cancer management and encourages an attempt to continuously improve these strategies to provide patients with better survival chances and quality of life.

Graphical Abstract